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Pulmonary arterial hypertension is a rare disease, which requires a high index of suspicion to diagnose when patients initially
present. Initial symptoms can be nonspeciﬁc and include complaints such as fatigue and mild dyspnea. Once the disease is
suspected, echocardiography is used to estimate the pulmonary arterial (PA) pressure and to exclude secondary causes of elevated
PA pressures such as left heart disease. Right heart catheterization with vasodilator challenge is critical to the proper assessment
of pulmonary hemodynamics and to determine whether patients are likely to beneﬁt from vasodilator therapy. Pathologically,
the disease is characterized by deleterious remodeling of the distal pulmonary arterial and arteriolar circulation, which results in
increased pulmonary vascular resistance. In the last ﬁfteen years, medications from three diﬀerent classes have been approved
for the treatment of pulmonary arterial hypertension. These include the prostanoids, endothelin receptor antagonists, and
phosphodiesterase-5 inhibitors.
1.Pathophysiology
Pulmonary arterial hypertension (PAH) is a progressive
incurable disease that is characterized by extensive remod-
eling of the pulmonary circulation predominantly in the
distal pulmonary arteries and arterioles. Proliferation of
pulmonary vascular endothelial and smooth muscle cells
leads to intimal and medial thickening of the pulmonary
resistance vessels [1]. In some places, these changes are so
severe that they result in near obliteration of the vascular
lumen. These diﬀuse vascular changes increase resistance to
blood ﬂow through the lungs. As the disease progresses, the
right ventricle becomes incapable of adequately increasing
pulmonary blood ﬂow during exercise and patients begin
to notice exertional dyspnea. Eventually, the rise in pul-
monary vascular resistance (PVR) leads to right ventricular
failure, and cardiac output begins to fall even under resting
conditions. In its ﬁnal stages, patients become severely
debilitated and are unable to perform nearly any activity
withoutdyspneaorchestpain.Ifleftuntreated,mostpatients
progress to overt right heart failure and death within 3 years
of diagnosis [2].
Although PAH is a rare disease, it often strikes patients
who are otherwise healthy in the middle of their life. Its
devastating impact on the lives of thousands of people has
led to an intense focus of research in pulmonary vascular
biology over the last quarter century that has resulted in
the development of numerous new therapies that have
improved the prognosis considerably. Unfortunately, a cure
for PAH has not yet been forthcoming and long-term
survival remains poor. Even with modern medical therapy,
most patient experience progression of their disease and
many are referred for lung transplantation. The discovery
this decade of a genetic defect that is associated with a
substantial number of cases has raised the hope that a cure
for PAH may eventually be found [3, 4].
The pathogenesis of PAH remains unclear. However,
several important imbalances in mediators of pulmonary
vascular cell growth and apoptosis have been described.
Patients with PAH demonstrate a decrease in the synthesis
of prostacyclin. This potent pulmonary vasodilator also has
important inhibitory eﬀects on platelet aggregation and
cellular proliferation. Patients with PAH have decreased
pulmonary expression of prostaglandin synthase, the major2 Pulmonary Medicine
enzyme responsible for its synthesis from the arachidonic
acid pathway. They also have a reduction in the circulating
levels of PGI2 relative to circulating levels of thromboxane
[5]. These changes cause a state of prostacyclin insuﬃciency
in patients with PAH and form the rationale for the use of
prostacyclin replacement therapy in the treatment of PAH.
Endothelin is a potent vasoconstrictor and smooth
muscle mitogen secreted by the pulmonary endothelium.
Immunohistochemistrystudieshavedemonstratedincreased
expression of endothelin in the obliterative vascular lesions
found in the lungs of patients with PAH [6]. Circulating
levels of endothelin are also increased in PAH patients
and correlate with disease severity [7]. Endothelin receptor
antagonists were the ﬁrst orally active agents approved for
the treatment of PAH and work by blocking the mitogenic
and vasoconstrictive eﬀects of ET-1 on the pulmonary
circulation.
In the healthy person, the pulmonary vasculature dilates
in response to increased ﬂow allowing the lung to accommo-
date a marked increase in blood ﬂow during exercise without
much of a rise in PA pressure. Synthesis and release of nitric
oxide (NO) by endothelial nitric oxide synthase (eNOS) in
thepulmonaryvascularendotheliumplaysanimportantrole
in ﬂow-mediated vasodilation in the pulmonary circulation.
Patients with PAH have decreased pulmonary expression of
eNOS and decreased levels of NO in exhaled air, raising the
possibilitythatdecreasedNOsynthesiscontributestotherise
in PVR [8, 9]. The biologic eﬀects of NO are mediated via
bindingtosolubleguanylatecyclaseandgenerationofcGMP.
Several studies suggest that the activity of phosphodiesterase
5,themajorenzymeresponsibleforthemetabolismofcGMP
is increased in animal studies of PH [10]. Inhibition of
cGMP metabolism via PDE5 inhibitors is the most recent
therapeutic strategy to be developed for the management of
PAH.
2. DiseaseClassiﬁcation
ThecurrentaccepteddeﬁnitionofPAHisameanPApressure
of greater than 25mmHg with a mean pulmonary capillary
wedge pressure of less than 15mmHg and a pulmonary
vascular resistance (PVR) of >3 Woods units. Elevation in
peak PA pressure reported on transthoracic echocardiogram
is not uncommon, but in the great majority of cases, it is
not caused by PAH. A number of pathological states can
elevate PA pressures, most notably chronic heart and lung
diseases. During the past several decades, the World Health
Organization (WHO) has proposed a new terminology to
describe the various forms of pulmonary hypertension. The
most recent update to this classiﬁcation system was the 4th
World Symposium on Pulmonary Hypertension in Dana
Point, California, in 2008 [11]( Table 1).
WHO group 1 is termed PAH and is characterized by a
diﬀuse pulmonary vasculopathy of the pulmonary arteries
and arterioles that is progressive in nature and results in
marked increases in the transpulmonary pressure gradient.
This group is further subdivided into idiopathic PAH (IPAH,
originally described as primary pulmonary hypertension)
and heritable PAH. The latter is used to describe PAH
associated with a number of genetic mutations that have
been linked to the development of PAH [3, 4]. PAH occurs
with increased frequency in patients with connective tissue
disease, particularly the limited cutaneous form of sclero-
derma. Other diseases associated with a high incidence of
PAH include portal hypertension, HIV infection, congenital
lefttorightintracardiacshuntsandtheuseofsomeanorectic
drugs. PAH that occurs in patients with these diseases is
referred to as associated PAH (APAH). Although the etiology
of IPAH, heritable PAH, and the APAH may vary, they all
have in common a diﬀuse vasculopathy of the pulmonary
arterial circulation that is both progressive and severe, and
thus are included in the same WHO group. All of the
presently available therapies for pulmonary hypertension
have indications that are limited to WHO group 1 and this
is the form of pulmonary hypertension that will be discussed
in this paper.
WHO group 2 refers to elevation of PA pressure that
is caused by an increase in pulmonary venous pressure
from left-sided heart disease. This type of pulmonary
hypertension is termed pulmonary venous hypertension and
ischaracterizedbyanearlynormalpulmonaryvascularresis-
tance (<3 Woods Units). WHO group 3 includes pulmonary
hypertension that occurs with chronic lung diseases such as
emphysema, interstitial lung disease, and sleep disordered
breathing. PA pressure elevation is usually moderate in this
group and often reﬂects the severity of the underlying lung
disease.WHOgroup4referstopulmonaryhypertensionthat
occurs in association with venous thromboembolic disease.
The last WHO group is reserved for a variety of diseases
known to be associated with pulmonary hypertension for
unclear reasons such as pulmonary sarcoidosis.
In addition to the etiological grouping, the WHO also
uses a grading score for functional class based on the
model developed for heart failure by the New York Heart
Association. Patients are designated as one of four functional
classiﬁcations based on the severity of their dyspnea and
physical limitations (Table 2). The WHO functional clas-
siﬁcation is used as an end point in PAH clinical trials
and routinely during oﬃce visits as a subjective measure of
disease progression.
3. Epidemiology
Idiopathic PAH is the most common form of the disease
aﬀecting 40%–50% of the patient in WHO diagnosis group
1. The estimated incidence of IPAH ranges from 7–50 per
million [12, 13]. Approximately 2/3 of all PAH patients are
female. PAH can occur at any age, but in a US-based registry,
the peak incidence occurred during the fourth and ﬁfth
decades of life [2]. Approximately 6%–10% of patients with
idiopathicPAHmayhaveafamilyhistoryofPAHandgenetic
screening has identiﬁed mutations in the bone morphogenic
protein type II receptor in up to 25% of IPAH patients.
Known exposure or abuse of certain drugs or toxins such as
fenﬂuramine, amphetamines, cocaine, methamphetamines,
and rapeseed oil have been associated with an increase risk of
PAH. PAH is also seen with increased frequency in a handful
ofdiseasesasdescribedaboveandinhemolyticanemiassuchPulmonary Medicine 3
Table 1: 4th World Symposium on Pulmonary Hypertension Classiﬁcation 2008.
(1) Group 1 pulmonary arterial hypertension
(1.1) Idiopathic (IPAH)
(1.2) Heritable
(1.2.1) BMPR2
(1.2.2) AKL1, endoglin (with or without heredity hemorrhagic telangiectasia)
(1.2.3) Unknown
(1.3) Drug and toxin induced
(1.4) Associates with (APAH)
(1.4.1) Connective tissue disease
(1.4.2) Human immunodeﬁciency virus (HIV) infection
(1.4.3) Portal hypertension
(1.4.4) Congenital heart disease
(1.4.5) Schistosomiasis
(1.4.6) Chronic hemolytic anemia
(1.5) Persistent pulmonary hypertension of the newborn
1  Pulmonary veno-occulsive disease (PVOD) and/or pulmonary capillary hemangiomatosis
Group 2 Pulmonary hypertension due to left heart disease
(2.1) Systolic dysfunction
(2.2) Diastolic dysfunction
(2.3)Valvular disease
Group 3 Pulmonary hypertension due to lung disease and/or hypoxia
(3.1) Chronic obstructive pulmonary disease
(3.2) Interstitial lung disease
(3.3) Other pulmonary diseases with mixed restrictive and obstructive pattern
(3.4) Sleep disordered breathing
(3.5) Alveolar hypoventilation disorders
(3.6) Chronic exposure to high altitudes
(3.7) Developmental abnormalities
Group 4 Chronic thromboembolic pulmonary hypertension
Group 5 pulmonary hypertension due to unclear multifactorial mechanisms
(5.1) Hematological disorders: myeloproliferative disorders, splenectomy
(5.2) Systemic disorders: sarcoidosis, pulmonary langerhans cell histiocytosis, lymphangioleiomyomatosis, neuroﬁbromatosis,
vasculitis.
(5.3) Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders.
(5.4) Other: tumor obstruction, ﬁbrosing mediastinitis, chronic renal failure on dialysis.
as sickle cell disease and thalassemia. Although uncommon
indevelopedcountries,theleadingcauseofPAHintheworld
is schistosomiasis.
4. ClinicalPresentation
Prompt diagnosis of PAH in an early stage is important
so that treatment may be started before right heart failure
occurs. However, time to diagnosis once symptoms develop
istypicallylongandisimpactedbythelackofspeciﬁcdisease
symptoms and the rarity of the disease that results in a
low level of clinical suspicion. Thirty years ago, the mean
time between symptom onset and diagnosis was 2 years [2].
Data from more recent registries suggest that this delay in
diagnosis persists despite increased recognition and the wide
spread availability of echocardiography [12, 14]. Patients
with APAH may be diagnosed earlier than IPAH due to
awareness of the association with certain comorbid diseases.
Initial symptoms of PAH are usually subtle and nonspeciﬁc
(see Figure 1). Patients often report fatigue, weakness, and
shortnessofbreathwithexertion.Typically,apatientwillfeel
as though they are out of shape and that their fatigue is due
to their lifestyle, aging, or other illnesses and at this point
canstillperformmostactivities.Whensymptomsprogressto
the point that the patient is limited with normal activities or
has trouble keeping up with peers and family members, they
frequently seek medical care. Delay in diagnosis typically
occurs due to the broad diﬀerential diagnosis of shortness
of breath and fatigue. Initial evaluation often reveals no
obvious abnormality leaving the patient with a diagnosis
of deconditioning or malingering. Failure to ﬁnd a cause4 Pulmonary Medicine
Table 2: World Health Organization Functional Class of PAH.
Class I: Patients with PAH that causes no limitations on physical activities. Routine physical activity does not cause increased dyspnea,
chest pain, fatigue, or presyncope.
Class II: Patients with PAH that causes mild limitations on physical activities. Patients are comfortable at rest but routine physical
activity results in increased dyspnea, chest pain, fatigue, or syncope.
Class III: Patients with PAH that have marked limitations on physical activities. Patients are comfortable at rest, but less than routine
physical activity results in dyspnea, chest pain, fatigue, or palpitations.
Class IV: Patient with PAH that results in the inability to perform any physical activity without symptoms. These patients may have
signsof right heart failure.Dyspnea withorwithout fatigue maybe presentat rest,andsymptomsareincreased byany physical activity.
Raynaud’s phenomenon (10%)
Palpitations (5%)
0%)
Progressive onset of
exertional dyspnea
(60%)
Chest pain or
discomfort (17%)
Dizziness and light-
headedness; possible
history of near
syncope or syncope
(13%)
Fatigue (19%)
P r e s e n t i n gs y m p t o m so fP A H
Ortner’s syndrome:
hoarseness from compression
of left recurrent laryngeal
nerve by enlarged pulmonary
artery (<1%)
Symptoms are often non-speciﬁc
Figure 1
may frustrate the patient and cause them to avoid seeking
additional medical care. In the absence of any identiﬁable
pulmonary disease, most patients are eventually sent for
echocardiogram that usually detects elevated PA pressure or
impaired RV function. As the disease progresses, patients
may complain of constant fatigue, shortness of breath
and chest pain or heaviness at rest, palpitations, dizziness,
peripheral edema, and exertional syncope.
When PAH is suspected from the patient’s symptoms or
detected by echocardiogram performed for other reasons,
further evaluation should start with a complete history and
physical exam. A thorough interview may reveal a family
history of early death due to heart failure or other events
suggestive of pulmonary hypertension. A history of other
heart and lung diseases, connective tissue disease, venous
thrombosis, pulmonary embolism, or hypercoagulopathy
should be sought. Patients should be questioned about risk
factors for HIV infection, hepatitis, or cirrhosis and asked if
they are aware of any congenital or rheumatic heart disease
and an assessment should be made regarding the likelihood
of sleep disordered breathing. Finally, patients should be
questioned about previous use of amphetamines or other
appetite suppressants and travel to or immigration from
countries known to be endemic for schistosomiasis.
Physical signs of elevated PA pressure are few and may
be subtle. Pulmonary hypertension often results in enough
tricuspid regurgitation to produce a systolic murmur best
heard at the right sternal border. The second heart sound
is often split due to enlargement of the right ventricle and
the pulmonic component may be accentuated [15]. Signs
of increased right-sided pressure such as jugular venous
distension,hepatojugularreﬂex,andarightventricularheave
developasthediseaseprogresses.Inadvancedstages,patients
develop severe lower extremity edema, ascites, and cyanosis.
The examiner should also look for signs of connective
tissue diseases such as malar rash, telangiectasias, calci-
nosis, sclerodactyly, and Raynaud’s disease. Evidence of liver
cirrhosis or portal hypertension and other diseases that
can contribute to the development of pulmonary hyper-
tension such as thyroid disease, obstructive sleep apnea,
and hemolytic anemia should be sought. Signs of chronic
heart disease, pulmonary ﬁbrosis, or emphysema suggestPulmonary Medicine 5
that patients may have pulmonary venous hypertension
or pulmonary hypertension associated with chronic lung
disease rather than PAH.
5.DiagnosticTesting
Patients are most often referred for evaluation of pulmonary
hypertension because of progressive dyspnea that is not
readily explained by other diseases or because elevated
PA pressure was found during an echocardiogram. The
approach to diagnosis is similar in both scenarios. An ECG
and chest ﬁlm are helpful in excluding subclinical heart
or lung disease and may provide additional information
about the severity of the patient’s PAH. Signs of elevated
right-sided pressure and right heart strain such as right
axis deviation, increased p-wave amplitude in lead 2 and t-
wave inversion in the precordial leads suggest more severe
pulmonary hypertension. Enlarged right ventricle and prox-
imal pulmonary arteries can be seen on chest ﬁlm in some
patients and peripheral pruning of the pulmonary vessels
maybeapparent.Increasedﬁllingoftheretrosternalairspace
on lateral chest ﬁlm suggests right ventricular enlargement.
Hilar adenopathy may suggest sarcoidosis.
Pulmonary function tests should be done to help exclude
obstructive or restrictive lung disease and obtain a baseline
measure of diﬀusion capacity. Adequate oxygenation should
beconﬁrmedbypulseoximetryorarterialbloodgasanalysis.
When suspected, hypercarbia should be excluded by arterial
or venous blood gas analysis. The 6 minute walk test has
become a mainstay of evaluating PAH patients and the
6 minute walking distance is the most frequent primary
eﬃcacy outcome measured in clinical trials of presently
available PAH therapies. The baseline 6 minute walking
distance should be established ideally before initiating
treatment. Change in blood pressure, pulse and oxygen
saturation should be recorded along with the Borg dyspnea
index. Patients who have a fall in oxygenation saturation are
more likely to have pulmonary vascular disease. Inability to
increase blood pressure suggests impaired cardiac function.
A formal sleep study may not be necessary in all patients but
should be considered in those with symptoms suggestive of
obstructive sleep apnea or other forms of sleep disordered
breathing.
Laboratorybloodtestsimportantintheinitialevaluation
of PAH include HIV test, liver function tests, thyroid
function tests, and serologies to rule out lupus, scleroderma,
and rheumatoid arthritis. Abaseline BNP and serumsodium
may be helpful in monitoring disease progression [16, 17].
Sexually active women of child-bearing age may want to
have a serum pregnancy test before starting some medical
therapiesforPAH.AV/Qscanisnecessarytoexcludechronic
thromboembolic disease, pulmonary veno-occlusive disease,
or other disorders that may obstruct the pulmonary vascula-
ture. A pulmonary angiogram or CT pulmonary angiogram
is often used instead but is not as sensitive in detecting
chronic thromboembolic disease of distal pulmonary vessels.
A good quality transthoracic echocardiogram is
extremely useful in evaluating pulmonary hypertension
[18, 19]. Right ventricular systolic pressure can be calculated
by measuring the speed of the regurgitant tricuspid jet using
Doppler ultrasound. Right atrial pressure is estimated by
looking at the degree of collapse of the inferior vena cava
during inspiration. Adding the 2 together provides peak
right ventricular pressure that in the absence of signiﬁcant
pulmonary valvular disease closely reﬂects peak PA pressure.
Although attention is often focused on the estimated PA
pressure, important information is also obtained from the
evaluation of cardiac chamber sizes and function. Right
atrial and or ventricular enlargement suggests chronic
elevation of right sided ﬁlling pressures. Right ventricular
hypokinesis is an indication of impaired right ventricular
systolic function. Deviation of the intraventricular septum
into the left ventricle during diastole is often described
as right ventricular pressure overload or a “D” shaped
intraventricular septum and indicates that right ventricular
end diastolic pressure has exceeded left ventricular end
diastolic pressure. Pericardial eﬀu s i o ni ss e e ni nl a t e rs t a g e s
of PAH and is associated with a poor prognosis [20].
The echocardiogram can also help look for left-sided
heart disease that may elevate PA pressure by increasing
pulmonary venous pressures. Enlargement of the left atrium
suggests pulmonary venous hypertension or mitral valve
disease. Decreased left ventricular systolic function is readily
apparent when present. Left ventricular hypertrophy raises
the concern of pulmonary venous hypertension from dias-
tolic dysfunction and some echocardiographers will report
impaired diastolic ﬁlling of the left ventricle by examining
the pattern of blood ﬂow through the mitral valve during
diastole. Findings such as these should alert the clinician to
the possibility of left sided heart disease and consideration of
additional cardiac studies.
Deﬁnitive diagnosis of PAH cannot be made without
accurate measurement of PA pressure and an assessment
of pulmonary venous pressure and cardiac output. At the
present time, this essentially requires right heart catheteri-
zation. Right heart catheterization for the initial evaluation
of PAH has become the standard of care as described
by the recommendations in the Dana Point 2009 WHO
consensus as well as by guidelines written and adopted by
the American College of Cardiologists, American Thoracic
Society, and the American College of Chest Physicians [21].
In addition, many insurance companies have adopted these
guidelines when approving payment for diagnostic workup
and treatment of PAH.
Some clinicians rely on echocardiogram to make the
diagnosis of PAH because it is less invasive, but because
of the rarity of PAH relative to that of other diseases that
increase peak PA pressure, it is necessary to demonstrate
that the elevation in PA pressure is due to increased PVR.
This can only be done by direct catheterization of the
pulmonary artery, measurement of PA pressure and down-
stream pulmonary venous pressure using the pulmonary
artery occlusion technique, and accurate measurement of
cardiac output. It is also important to realize the PA
pressure is dependent on cardiac output and that a moderate
elevation of PA pressure on echocardiogram can be seen
in severe PAH when right ventricular failure occurs. Right
heart catheterization also allows for evaluation of left to6 Pulmonary Medicine
right intracardiac shunts and acute reactivity to pulmonary
vasodilators.
Medications used for vasodilator testing while the right
heart catheter is in place include inhaled nitric oxide,
intravenous epoprostenol, or intravenous adenosine. The
deﬁnition of a positive vasodilator response is a greater than
10% decrease in pulmonary artery mean pressure to an
absolute mean value of less than 40mm/Hg with no decrease
in cardiac output. In addition to acute vasodilator testing,
patients with mild or moderate pulmonary hypertension are
sometimes exercised with the right heart catheter in place to
determine if PA pressure rises during exercise.
5.1. Treatment. Over the last 15 years, 9 diﬀerent drugs
representing 3 new classes of medication have been devel-
oped for the treatment of PAH (Figure 2). This explosion
in drug development was spurred by a marked increase
in the understanding of pulmonary vascular biology that
occurred in the last quarter of the 20th century. Prior to the
approval of intravenous epoprostenol at the end of 1995, the
only medications available to treat PAH were vasodilators
designed to treat systemic hypertension. These agents such
as hydralazine, ACE inhibitors and calcium channel blockers
generally demonstrated greater vasodilatory eﬀect on sys-
temic than pulmonary vessels causing systemic hypotension
andincreasingrightheartstrainastherightventricleworked
to increase cardiac output to compensate for the fall in
systemic vascular resistance. A small minority of patients
withPAHshowmarkedimprovementinpulmonaryvascular
resistance and cardiac output in response to calcium channel
blockers. These patients, best described by Rich et al. [22]
showexcellentresponsetolong-termtreatmentwithcalcium
channel blockers alone and may represent a subset of PAH
patients with increased pulmonary vascular tone as opposed
to pulmonary vascular remodeling. Although more recent
studies [23] estimate that this group of patients represents
less than 10% of all WHO group 1 PAH patients, their iden-
tiﬁcationiswarrantedduetotheirmuchimprovedprognosis
and successful management with calcium channel blocker
agents alone. For this reason, it is highly recommended
that all patients undergo acute vasodilator reactivity testing
in the catheterization lab with short acting agents such as
inhaled nitric oxide, intravenous epoprostenol, or adenosine
as part of their initial evaluation. Those who have a positive
pulmonary vasodilator response deﬁned as a decrease in
mPAP of 10mmHg or greater and a decrease in mPAP to
below 40mmHg should be considered for treatment with
calcium channel blockers alone. For the great majority of
patients who do not respond to acute pulmonary vasodilator
challenge, one of the following medical therapies described
below may be considered.
5.1.1. Phosphodiesterase Inhibitors. As mentioned previously,
patients with pulmonary hypertension have reduced expres-
sion of endothelial nitric oxide synthase in the pulmonary
vasculature [8]. While nitric oxide is a potent vasodilator,
chronic administration of nitric oxide for the treatment
of pulmonary hypertension is impractical. Nitric oxide’s
Medications for PAH
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Figure 2
vasodilating properties are mediated through the generation
of cyclic GMP (cGMP). Phosphodiesterases are a family of
enzymes that hydrolize cGMP representing the major route
of cGMP metabolism. The PDE-type 5 isoform is the pri-
mary PDE responsible for metabolizing cGMP in the corpus
cavernosum of the penis and in the pulmonary arteries.
Activity of PDE-5 may be upregulated in PAH causing a
relative deﬁciency of cGMP in pulmonary vascular smooth
muscle. PDE-5 inhibitors increase intracellular cGMP levels
leading to a reduction in intracellular calcium levels and
subsequent smooth muscle relaxation causing vasodilation
in resistance arterioles.
Sildenaﬁl was the ﬁrst PDE5 inhibitor approved for the
treatment of PAH. It had previously demonstrated potential
in the treatment of pulmonary hypertension in animal
models [24] and as adjunctive or sole treatment in human
pulmonary hypertension [25, 26]. The largest clinical trial
was a double-blind, placebo-controlled study of 278 patients
from 53 centers throughout the world [27]. Patients had
idiopathic PAH or PAH associated with connective tissue
disease, or congenital systemic-to-pulmonary shunts. At
baseline, 39% of patients were in WHO functional class
II, and 58% were in class III. They were randomized to
receive placebo or one of three doses of sildenaﬁl (20, 40, or
80mg) orallythree times daily fortwelve weeks. The primary
endpoint was the change over 12 weeks in the 6-minute walk
distance.
Analysis of the primary endpoint demonstrated an
increase in walk distance for all groups randomized to
sildenaﬁl. At week 12, the mean placebo-corrected eﬀects
were 45m, 46m, and 50m for those in the 20mg, 40mg,
a n d8 0m gg r o u p sr e s p e c t i v e l y( P<0.001 for all treatment
groups compared to placebo). Analysis of hemodynamic
data demonstrated a signiﬁcant improvement in pulmonary
vascular resistance with sildenaﬁl, and there was a dose-
response eﬀect with the 80mg group demonstrating the
greatest reduction (−261 dyn∗sec∗cm−5 with 80mg as com-
pared with an increase of 49dyn∗sec∗cm−5 in the placebo
group). The improvement in cardiac index also exhibited a
dose response relationship although the improvement in thePulmonary Medicine 7
20mg group compared with placebo did not reach statistical
signiﬁcance. The incidence of clinical worsening did not
diﬀer between the two treatment groups. Two hundred ﬁfty
nine of the patients enrolled in a long-term extension study
of 80mg of sildenaﬁl three times daily. During a one year
follow up, 15 of those patients withdrew, and 14 died. Of
the remaining 230 patients, eight were receiving additional
therapy. Analysis of the other 222 patients revealed that
the mean change from baseline in the six-minute walking
distance was 51 meters (95% CI of 41 to 60).
Tadalaﬁl is an orally administered selective PDE5
inhibitor, which has the considerable advantage of once daily
dosing. Human data on the use of this compound in patients
with PAH remains more limited than with sildenaﬁl. The
Pulmonary Arterial Hypertension and Response to Tadalaﬁl
(PHIRST) Study Group randomized 405 treatment-naive
or bosentan treated patients with PAH to placebo or to
tadalaﬁl2.5,10,20,or40mgorallyoncedaily[28].Thestudy
population included patients with idiopathic or heritable
PAH, or PAH associated with connective tissue disease,
HIV infection, anorexigen use, or congenital systemic-to-
pulmonary shunt. Randomization was stratiﬁed for baseline
walking distance, type of PAH, and bosentan use. The
primary end point was the change from baseline in the 6-
minute walk distance.
Tadalaﬁl at doses of 10, 20, and 40mg, compared with
placebo, improved the six-minute walk distance in a dose-
dependent manner at week 16 (mean placebo-corrected
treatment eﬀects of 14m, 20m, 27m, and 33m for the 2.5,
10, 20, and 40mg groups, resp.). However, the 40mg dose of
tadalaﬁl was the only one that reached the prespeciﬁed value
of statistical signiﬁcance of P<0.01. In addition, time to
clinical worsening was signiﬁcantly improved in the tadalaﬁl
40mg group (P = 0.041). Fifty-three percent of the patients
were on background therapy with bosentan during the
trial. Bosentan-na¨ ıve patients given 40mg of tadalaﬁl had a
greaterincreaseinwalkingdistance(44meters)thanpatients
on background bosentan (23 meters). Further supporting
the idea of a blunted improvement in exercise capacity
for patients already receiving PAH therapy, bosentan-na¨ ıve
patients tended to have better results in all secondary end
points. The improvement in 6-minute walking distance was
sustained for 10 months in a subgroup of patients who had
been enrolled in a long-term extension study of 20 or 40mg
tadalaﬁl. Of the 213 patients who had completed 44 weeks of
tadalaﬁl therapy at the time of publication, the mean change
in 6-minute walking distance was 37 meters at 16 weeks and
38m after 44 weeks.
5.2. Prostacyclins. Prostacyclin was discovered in 1976 and
was found to have vasodilating, antiplatelet, and antiprolif-
erative properties. The chemical analogue epoprostenol was
synthesizedandtestedinthesameyear[29].Theﬁndingthat
patients with PAH were deﬁcient in prostacyclin leads to a
natural interest in the use of epoprostenol for therapeutic
purposes.Promisingresultsfromearlycasereportsandsmall
series of patients with PAH treated with epoprostenol [30]
as well as a small randomized trial comparing continuous
epoprostenolwithconventionaltherapyagainstconventional
therapy alone [31] lead to a landmark multicenter ran-
domized controlled trial that was published in 1996 [32].
That 12-week open trial enrolled 81 patients with NYHA
functional class III or IV PAH. Patients were randomized to
receive continuous intravenous epoprostenol plus conven-
tional therapy or conventional therapy alone. Conventional
therapy consisted of anticoagulants, calcium channel block-
ers, cardiac glycosides, and supplemental oxygen. Endpoints
for the study were the eﬀect of epoprostenol on exercise
capacity, quality of life, hemodynamics, and survival. The
epoprostenol-treatedgrouphadstatisticallysigniﬁcantbetter
outcomes for all of these over the 12-week study period.
The median 6-minute walk distance improved from 315
meters to 362 meters in the epoprostenol-treated group,
while it decreased from 270 meters to 204 meters in the
conventionaltreatmentgroup(P<0.002forthecomparison
of the treatment groups). With adjustment for baseline
diﬀerencesin6-minutewalkdistanceandvasodilatoruse,the
epoprostenol treated group still exhibited a median increase
of 31 meters, while the conventional therapy group exhibited
am e d i a nd e c r e a s eo f2 9m e t e r s( P<0.02). Quality of life
as measured by the Chronic Heart Failure Questionnaire
improved only in the epoprostenol-treated group. The mean
PA pressure decreased 4.8 ± 1.3mmHg in the epoprostenol
treated group, while it increased 1.9 ± 1.6mmHg in the
conventional therapy group (diﬀerence between treatment
groups of −6.7mmHg, 95% CI −10.7 to −2.6mmHg).
Eightpatientsrandomizedtotheconventionaltherapygroup
died during the 12 weeks of the study, but none of those
assign to treatment with epoprostenol died (P<0.05).
Side eﬀects are common at higher doses of prostacyclin
infusion and occur as a result of systemic vasodilation. The
most common side eﬀects include facial ﬂushing, headache,
and jaw pain, especially when chewing. Other adverse events
include diarrhea and bone pain in the legs and bottom of
the feet. The side eﬀects were reported more frequently in
the group that received epoprostenol. Serious complications
includedfourepisodesofnonfatalcatheter-relatedsepsisand
one episode of nonfatal catheter related thrombosis resulting
in a paradoxical embolism.
Epoprostenol has also been shown to be eﬀective in the
treatment of PAH associated with scleroderma. A short-
term hemodynamic study of the eﬀect of intravenous
epoprostenol in patients with PAH associated with scle-
roderma demonstrated reductions in pulmonary vascular
resistance and an increase in cardiac output [33]. Another
single-center, uncontrolled study in patients with connective
tissue disease and severe PAH demonstrated the beneﬁts
of continuously infused epoprostenol on hemodynamics
and exercise capacity [34]. The pivotal trial of continuous
epoprostenol for the treatment of scleroderma associated
PAH was a randomized, open-label study of 111 patients
from 17 referral centers [35]. It compared the eﬀects
of epoprostenol as an addition to conventional therapy.
More than 90% of the patients in each group were in
NYHA functional class III or IV. Importantly, patients with
more than mild associated interstitial lung disease were
excluded. Over the 12-week study period, the median 6-
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the epoprostenol plus conventional therapy group, while it
decreasedfrom240to192metersintheconventionaltherapy
alone group (P<0.001). Hemodynamic assessment demon-
strated a decrease in mean PA pressure of 5.0 ± 1mmHgin
the intervention group, while the conventional therapy arm
demonstrated an increase in mean PA pressure of 0.94 ±
1.1mmHg(diﬀerencebetweengroupsof −5.97mmHgwith
95% CI of −8.98 to −2.96mmHg). Cardiac index increased
0.5 ± 0.08L/min/m2 with the addition of epoprostenol,
while it decreased 0.1 ± 0.08L/min/m2 in the control arm
(diﬀerence between groups of 0.60L/min/m2 with 95% CI of
0.39 to 0.81L/min/m2) .A d v e r s ee v e n t sr e l a t e dt ot h eu s eo f
a continuous intravenous infusion system for epoprostenol
included 4% incidences of sepsis, cellulitis, hemorrhage,
and pneumothorax. Similar numbers of patients died in
each group, and minor side eﬀects related to the use of
epoprostenol were in keeping with other studies.
Epoprostenol’s short plasma half-life of approximately 3
minutes mandates continuous intravenous infusion that is
both cumbersome for the patient and associated with poten-
tially serious catheter-related complications. Treprostinil is
a stable prostacyclin analogue that is chemically stable at
room temperature and has a half-life of three to four hours.
These properties permit continuous subcutaneous infusion
via a needle that can be placed under the skin by the patient.
Initial data, published in abstract form, demonstrated the
safety and beneﬁcial acute hemodynamic eﬀects of this
approach to prostacyclin therapy [36, 37]. The large phase
III study that lead to approval of subcutaneous treprostinil
for treatment of patients with PAH randomized 470 patients
(approximately 80% of whom were in NYHA functional
class III) from centers throughout the world [38]. It was
the ﬁrst double-blind, placebo-controlled trial involving
patients with PAH. Patients received conventional therapy
plus either continuous subcutaneous treprostinil or placebo
for 12 weeks. The primary eﬃcacy endpoint in this study
was 6-minute walking distance. In the treprostinil group,
the median improvement was 10 meters, while the placebo
group exhibited no signiﬁcant change. The diﬀerence in
median distance walked between the two groups was 16
meters (95% CI, 4.4 to 27.6 meters; P = 0.006). While the
overall treatment eﬀect was small, patients in the highest
quartile dose of treprostinil (>13.8ng/kg/min) had a placebo
adjusted increase in walking distance of 36.1 ± 10 meters.
Interestingly, the patients with the lowest baseline 6-minute
walking distance in the treprostinil group experienced the
greatest beneﬁt. Patients who walked less than 150 meters at
baseline experienced a treatment eﬀect of 51 ± 16 meters
(P = 0.002), while patients who walked more than 351
meters at baseline experienced no substantial treatment
eﬀect. These ﬁndings suggest that treprostinil infusion may
be more eﬀective when used at higher doses in patients with
more advanced PAH.
Analysis of cardiopulmonary hemodynamics in this
study demonstrated statistically signiﬁcant improvements
in all variables with treprostinil treatment. In particular,
cardiac index improved by 0.12L/min/m2 compared to a
decrement of 0.06L/min/m2 in the placebo group (P =
0.0001 for comparison of change from baseline), and the
mean PA pressure decreased 2.3 ± 0.5mmHgascompared
to an increase of 0.7 ± 0.6mmHg in the placebo group
(P = 0.0003 for comparison of change from baseline). The
treprostinil-treated group had a higher incidence of infusion
site pain (85% versus 27%) and also had a higher incidence
of classic prostacyclin related side eﬀects. Three patients
in the treprostinil-treated group experienced an episode
of gastrointestinal bleeding. Two of these patients had a
supratherapeutic international normalized ratio (INR), and
all of the episodes resolved without signiﬁcant consequences.
Subcutaneoustreprostinilinfusionallowsforthedelivery
of continuous prostacyclin infusion without the need for
a central catheter, and thereby eliminates the danger of
central venous catheter infection. At the same time, its
longer half-life provides a greater cushion of time for
restarting the infusion in the event that it is interrupted
because of pump failure or loss of intravenous access. These
advantages increase the number of patients who are eligible
for continuous prostacyclin infusion therapy. Unfortunately,
most patients experience some degree of discomfort at the
infusion site, and in approximately a quarter of patients, the
degree of discomfort is too great to continue therapy. In
addition to subcutaneous infusion, treprostinil can also be
used as a continuous intravenous infusion [39].
Prostacyclin analogues also act as eﬀective pulmonary
vasodilators when inhaled. Aerosolized prostacyclin was
developed to mitigate the incidence of systemic side eﬀects
that occur with prostacyclin therapy and to obviate the
need for subcutaneous or central venous access and teth-
ering the patient to a battery operated infusion pump.
Another potential advantage of inhaled prostacyclin is the
improvement of ventilation perfusion matching. This may
occur because the greatest pulmonary vasodilator eﬀect
occurs in areas of the lung that are well ventilated and
thereby reduces blood ﬂow to areas that are not. Several
early trials demonstrated the feasibility of this approach in
the treatment of PAH. The pivotal trial was performed in
Europe and randomized 203 patients with WHO functional
class III or IV pulmonary hypertension to inhaled iloprost
or placebo [40]. Most of the patients enrolled had WHO
group 1PAH, but nearly 1/3 of patients randomized to
iloprost had chronic thromboembolic pulmonary hyperten-
sion. Patients received inhalations of 2.5 or 5.0 micrograms
of iloprost 6 to 9 times per day as needed. The median
inhaled dose in the iloprost group was 30 micrograms per
day.
Given their desire for a robust measure of eﬃcacy
and the fact that continuous intravenous epoprostenol
had previously demonstrated a survival advantage, these
investigators chose a combined primary endpoint of an
improvement of at least one NYHA functional class and a
10 percent improvement in 6-minute walking distance. This
combined endpoint was met by 16.8 percent of the patients
who received iloprost as compared with 4.9 percent of the
patients who received placebo (P = 0.007). There were no
signiﬁcant diﬀerences amongst groups with diﬀerent types
of pulmonary hypertension. Adverse eﬀects were similar
between the two groups although there was a statistically
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group. These events were not associated with clinical deteri-
oration, and the authors concluded that the higher incidence
ofsyncopemayhaveresultedfromtreatedpatientsincreasing
theiractivitytooquickly.Giventheconcernthatintermittent
inhalations(asopposedtoacontinuousintravenousinfusion
ofaprostanoid)maynothaveadurableeﬀectthroughoutthe
day, the 12-week hemodynamic assessment included mea-
surement of preinhalation values. While measurements done
after iloprost inhalation showed the most improvement from
baseline compared to the placebo group, the pre-inhalation
change in PVR from baseline of −9 ± 275dyn·sec·cm−5
was still signiﬁcantly better than the 96 ± 322dyn·sec·cm−5
increase from baseline in the placebo group (P<0.01).
While inhaled iloprost oﬀers a safe and eﬀective form
of prostacyclin therapy for PAH without the diﬃculties
of continuous infusion, its short half-life and subsequent
requirement for at least 6 inhalations per day makes patient
compliance challenging. Each inhalation may take 10–15
minutes to set up and complete. Inhalation of a longer
acting prostacyclin may allow for less frequent treatments.
Findings from a pilot study of inhaled treprostinil demon-
strated that inhaled treprostinil had similar eﬃcacy but a
longer duration of action compared to inhaled iloprost [41,
42]. The pivotal trial of inhaled treprostinil for PAH was
a multicenter placebo-controlled double-blind study that
assessed its’ impact in patients already receiving oral therapy
with bosentan (125mg daily) or sildenaﬁl (at least 20mg
three times daily) [43]. Two hundred thirty-ﬁve patients
with idiopathic or familial PAH, or PAH associated with
collagen vascular disease, HIV infection, or anorexigen use
were enrolled and studied over 12 weeks. Nearly all patients
studied were in NYHA functional class III (98%) at the time
of enrollment. They were randomized to inhaled treprostinil
(up to 54 micrograms) or inhaled placebo four times daily,
and the primary end point was 6-minute walk distance at
12 weeks measured within 10 to 60 minutes after treprostinil
inhalation. Secondary end points included functional class,
quality-of-life indices and change in N-terminal probrain
natriuretic peptide (NT-proBNP) level.
Of the 235 patients randomized, 23 withdrew from the
study prematurely. Eight patients withdrew consent, while
the rest discontinued due to adverse events or worsening
disease. The between treatment median diﬀerence in change
from baseline in peak six-minute walk distance was 19
meters at week 6 (P = 0.0001) and 20 meters at week 12
(P = 0.0004). Importantly, there was evidence that beneﬁt
was maintained throughout the 6-hour interval between
treatments. The median improvement in 6-minute walking
distance measured just before inhalation of treprostinil was
14 meters at week 12 (P = 0.0066). Amongst the secondary
end points, only quality-of-life measures and NT-proBNP
demonstrated improvement with inhaled treprostinil com-
pared to placebo.
At the present time 3 diﬀerent prostacyclin medications
are approved for the treatment of PAH in the United
States and Europe. No head-to-head studies have been done
to compare the eﬃcacy of intravenous or subcutaneous
infusion versus intermittent inhalation. However, all appear
to be eﬀective to some degree in improving hemodynamics
and exercise capacity in PAH. At the present time, clinical
trials are being conducted with an orally active treprostinil
tablet. These trials may pave the way for the development of
a fourth route of prostacyclin administration.
5.3. Endothelin Receptor Antagonists. Endothelin was origi-
nally identiﬁed in 1985 as a vasoconstricting factor isolated
from bovine aortic endothelial cells [44]. In 1988, a Japanese
group synthesized the peptide and named it endothelin [45].
They noted that it was the “most potent vasoconstrictive
peptide so far reported”. Endothelin binds to two diﬀerent
cell surface receptors. ET-A mediates the vasoconstrictor
eﬀect of endothelin on vascular smooth muscle. In contrast,
ET-B is found predominantly on endothelial cells, where it
induces nitric oxide synthase and acts to clear endothelin
from the circulation.
The ﬁrst endothelin receptor antagonist (ERA) tested for
the treatment of PAH was bosentan, which is a nonselective
agent that has similar binding aﬃnity for ET-A and ET-B.
After a small initial double-blind placebo-controlled study
[46] demonstrated improvements in exercise capacity and
hemodynamics, a larger study that included multiple dosing
regimens waspublished in 2002 [47]. This study randomized
213 patients with either idiopathic PAH or PAH associated
with connective-tissue disease (approximately 90% of whom
were in functional class III) to placebo or Bosentan. The
bosentan group received 62.5mg twice daily for four weeks
followed by either 125 or 250mg twice daily for a minimum
of twelve weeks. The primary endpoint was the change in 6-
minute walking distance.
At the conclusion of sixteen weeks, 6 minute walking
distance decreased an average of 8 meters in the placebo
group and increased 36m in the combined bosentan groups
(mean diﬀerence of 44 meters; P<0.001). There was
a nonsigniﬁcant trend towards further improvement with
the 250mg dose as compared to 125mg. Bosentan also
signiﬁcantly increased the time to clinical worsening as
compared to placebo. The overall incidence of adverse events
between the two groups was similar with the exception
of a dose-dependent increase in the incidence of liver
transaminase elevation with bosentan therapy.
Ambrisentan is a selective ET-A receptor antagonist that
has the theoretical advantage of mitigating vascular smooth
muscle induced vasoconstriction without reducing the nitric
oxide production and endothelin clearance associated with
endothelin’s binding to the ET-B receptor. In addition, its
longer half-life allows for once daily dosing. The pivotal
trials of ambrisentan’s use in PAH (ARIES-1 and ARIES-
2)wereconcurrentrandomized,placebo-controlled,double-
blind studies which diﬀered in terms of the investigative sites
and doses of ambrisentan. ARIES-1 randomized patients in
North or South America to placebo or 5 or 10mg per day
of ambrisentan. ARIES-2 randomized patients in Europe,
the middle east, or Australia to placebo or 2.5 or 5mg of
ambrisentan.Inbothstudies,patientshadidiopathic PAHor
PAHassociatedwithconnectivetissuedisease,HIVinfection,
or anorexigen use and the primary endpoint was the change
in 6-minute walk distance from baseline to week 12. The
results of both studies were published together [48].10 Pulmonary Medicine
At 12 weeks, the six-minute walk distance increased in all
ambrisentan groups. The mean placebo-corrected treatment
eﬀects were 31 meters (P = 0.008) and 51 meters (P<0.001)
for the 5 and 10mg doses, respectively, in ARIES 1 and 32
meters (P = 0.022) and 59 meters (P<0.001) for the
2.5 and 5mg doses in ARIES-2. Improvements in secondary
end points such as time to clinical worsening, functional
class, symptom assessments, and B-type natriuretic peptide
measurements were also seen for the 5 and 10mg doses.
In order to assess the eﬀects of more sustained therapy,
these trials also included a long-term study that was open
to all patients who completed the initial study and all
placebo patients who discontinued because of early escape.
Of the 280 patients who completed 48 weeks of ambrisentan
monotherapy, the improvement from baseline in 6-minute
walk distance was 39 meters.
Athirdendothelin antagonist,sitaxsentan,demonstrated
promiseinPAHbasedonitsselectivityfortheET-Areceptor,
and on a lack of signiﬁcant interaction with sildenaﬁl.
However, the manufacturer withdrew it from all available
markets and halted further clinical trials in December 2010
due to problems with hepatotoxicity.
Both bosentan and Ambrisentan have been shown to
cause transient elevation of liver transaminases, and these
laboratory tests should be monitored at least monthly for as
long as the patient is taking them. The ERAs have also been
associatedwithsmalldecreasesinhemoglobinandarehighly
teratogenic. Sexually active patients on these medications
should use a double-barrier method of contraception, and
fertile woman should be monitored closely for pregnancy.
6. Combination Therapy and
Treatment Algorithms
Few clinical trials have compared the safety and eﬃcacy of
one PAH drug or one class of PAH drugs to another in a
head-to-head trial. Wilkins et al. [49] found no diﬀerence
in 6-minute walking distance in 20 patients treated with the
ERAbosentancomparedto20patientstreatedwithsildenaﬁl
for 12 weeks. However, the trial was not powered to detect
small diﬀerences in functional status or conducted long
enough to examine diﬀerences in survival. In the absence
of comparative trials, treatment algorithms for PAH have
been developed using expert opinion [50]. There is general
agreement that patients with WHO functional class II and
III disease can be treated initially with an oral ERA or
PDE inhibitor alone. Inhaled prostacyclins or subcutaneous
treprostinil infusion are other options. Those who improve
canbekeptontheirinitialtherapy.Forpatientswhoprogress
to or present in WHO functional class IV, intravenous
epoprostenol is recommended. Other patients who should
be considered for intravenous epoprostenol patients include
WHO class III patients who have elevated right atrial
pressure, decreased cardiac output or other signs of right
ventricular failure.
The use of a combination of drugs from diﬀerent PAH
classes is an area of great interest. Several randomized
placebo controlled trials have examined the beneﬁt of
adding a second PAH medication to patients who failed
to respond to or have deteriorated on their initial therapy
using a randomized placebo-controlled design [43, 51–53].
The favorable responses described in these trials may be
attributed to the combination of the initial therapy plus the
add on agent. However, it is also possible that patients in
these trials simply responded better to the second agent than
theﬁrst.Clinicaltrialsthatspeciﬁcallyexaminetheeﬃcacyof
a combination of medications to either drug alone have not
been completed, although one was recently initiated [54]. At
the present time, it is unclear whether patients who do not
respond to a given therapy should be switched to another
therapy or kept on their original therapy while another
therapyisadded(seeFigure 3).Ingeneral,thelaterapproach
is more often used due to the fear of deterioration after the
original therapy is stopped.
7.Follow-Up Care
Continued long-term care is an important aspect of patient
survival once diagnosis and PAH therapy has started.
Frequent oﬃce visit are a necessity for patients starting any
continuous infusion or inhaled therapy to ensure accuracy
and compliance to therapy. Patients starting on parenteral
therapy are seen biweekly to monthly when ﬁrst beginning
therapy. Once a patient’s condition has stabilized, they are
typically followed in the oﬃce every 1–3 months. Along with
frequent oﬃce visits, 6-minute walk tests, echocardiogram,
and plasma BNP levels are performed 2-3 times a year
or more often if the patient requires frequent titration of
parenteral therapy or addition or change in therapy due to
suboptimal treatment response.
Concurrent medications used for PAH patients include
diuretics to control peripheral edema as necessary, digoxin,
warfarin, and supplemental oxygen. Digoxin may improve
right ventricular contractility, but its clinical eﬀect is small
[56]. Some studies suggest that survival in PAH is improved
with long-term anticoagulation [22], but no adequately
powered study has explored this in a randomized placebo-
controlled fashion. Unless the patient is at increased risk of
bleeding or has other contraindications for long-term anti-
coagulant therapy, most physicians use low-dose warfarin
to target an INR or 1.5 to 2.0 in patients with IPAH. Little
data is available to suggest any beneﬁt of anticoagulation
in patients with APAH. Oxygen therapy is indicated for
patientswithsaturationsbelow91%-92%[57]Loweroxygen
saturations can increase PA pressures via hypoxic pulmonary
vasoconstriction.
Inpatient hospitalization may be required for patient
with worsening right heart failure and ﬂuid overload for IV
diuresis and stabilization of disease. If a patient’s condition
does not improve despite an aggressive course of therapy,
a repeat right heart catheterization may be warranted to
reassess pulmonary hemodynamics.
Referral for lung transplantation should be considered
soon after initial diagnosis and initiation of therapy, espe-
cially if there is a delay in adequate response to therapy.
Lung transplant evaluation should be completed early in
the course of therapy, as the evaluation process and wait
for suitable donor organ is lengthy, and the patients whoPulmonary Medicine 11
Supportive therapy and general
measures
Expert Referral (E/A)
Acute vasoreactivity test (A for IPAH)
(E/C for APAH)
WHO class I-IV
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Amlodipine, diltiazem
Sustained response
(WHO I-II)
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Oral anticoagulants (E/B)-IPAH/HPAP
Diuretics (E/A)
Oxygen (E/A)
Digoxin (E/C)
Supervised rehabilitation (E/B)
Acute responder
WHO class II WHO class III WHO class IV
A
sildenaﬁl
Ambrisentan,
Epoprostenol IV
B Tadalaﬁl Iloprost Inh
C Treprostinil SC
E/B Iloprost IV, treprostinil IV
Initial combination therapy
E/C
Not approved Treprostinil inh Treprostinil inh
Ambrisentan, bosentan,
Tadalaﬁl,treprostinil SC
Beraprost
Iloprost IV, treprostinil IV
Inadequate clinical response
Inadequate clinical response
Sequential combination therapy Prostanoids
Atrial septostomy (E/B)
and/or lung transplant
(E/A)
+(B) +(B)
+(B) ERA
Avoid excessive physical exertion
Birth control (E/A)
Psychological and social support (E/C)
Infection prevention (E/A)
Strength of
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PDE-5I
and nifedipine (B)
and nifedipine (B)
Nonresponder
bosentan and
and sildenaﬁl
Ambrisentan, bosentan,
sildenaﬁl and tadalaﬁl
epoprostenol IV, iloprost inh
Figure 3: Adapted from [55].
fail to respond to medical therapy can deteriorate suddenly.
Timing of lung transplant is important in that a patient must
be stable enough to tolerate transplant surgery but have a
worseningprognosiswithadecreasedlikelihoodofsurviving
without transplant.
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